Evaluaion the Short Term Effects of Advograf Plus Rapamiune After Kidney Transplantation

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
Cornerstone immunosuppressive therapy currently relies on immediate-release tacrolimus, a calcineurin inhibitor (CNI) that is potentially nephrotoxic and is more diabetogenic than cyclosporine A. A new formulation of tacrolimus has been launched: an extended-release formulation (Advagraf®/Astagraf XL®, Astellas company).
Epistemonikos ID: 4224a873720b15fae2d269f7e13c16d837ccc46b
First added on: Jun 25, 2025